TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01474928

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: patient role played community video
Description: Group two viewed the patient role played community video

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: both videos group
Description: Group three viewed both the knowledge and community videos

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pamphlet group
Description: Group four read an educational pamphlet only

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physician-led knowledge video
Description: Group one viewed a physician-led knowledge video

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community video group
Description: Group two viewed the patient role played community video

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: knowledge video
Description: Group one viewed a physician-led knowledge video
Study: NCT04039477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KZR-616
Description: Patients will receive KZR-616 SC once weekly. Patients assigned to Arm A will receive 30 mg for 13 weeks and patients assigned to Arm B will receive 30 mg for 1 week then 45 mg for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KZR-616
Description: Patients will receive KZR-616 SC once weekly. Patients assigned to Arm A will receive 30 mg for 13 weeks and patients assigned to Arm B will receive 30 mg for 1 week then 45 mg for 12 weeks
Study: NCT03970070

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Complete Perioperative Ostomy Self-Management Telehealth program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT01958307

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: The intervention program consists of four individual counseling modules focusing on diet, physical activity and weight monitoring (12th-16th, 16th-20th, 30th-34th week of gestation and 6th-8th week postpartum). The counseling sessions are given by carefully trained midwives or medical staff in combination with prenatal visits and follow a standardized curriculum. Women are provided with brochures including a list of adequate prenatal exercise programs and a pedometer. Furthermore, they receive a chart personalized according to their baseline BMI category to monitor weight development.
Study: NCT00806572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hOKT3gamma1(Ala-Ala)
Description: 3 cycles, six months apart, each consisting of 12 daily infusions with 455-1818ug/m2 hOKT3g1(Ala-Ala)
Study: NCT00784355

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Description: Surgery
Study: NCT02957526

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prompts to report symptoms via study app
Description: Weekly prompts to report aromatase inhibitor use in the previous 7 days and treatment-related adverse symptoms via the web-enabled study app.
Study: NCT03375788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesamorelin
Description: Tesamorelin F4 formulation 1.4mg daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Identical Placebo
Description: Placebo injection daily
Study: NCT02957526

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical Alerts
Description: : Reported symptoms may trigger an email alert to the participant's care team based on predetermined thresholds. Alerts based on certain response thresholds are generated to inform the patient's care team of any concerning responses or trends that emerge from the patient reported outcomes. These alerts will inform providers of particular patient-related adverse events or symptoms requiring an intervention prior to the point that emergent medical care is needed. Information in the alert emails will include the participant's Medical Reference Number (MRN), initials, date of birth, and details about the symptom(s) that generated the alert. Pod nurses instructed to respond to any clinical alerts (sent via email) as soon as possible following standard of care.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Alerts
Description: : Reported symptoms may trigger an email alert to the participant's care team based on predetermined thresholds. Alerts based on certain response thresholds are generated to inform the patient's care team of any concerning responses or trends that emerge from the patient reported outcomes. These alerts will inform providers of particular patient-related adverse events or symptoms requiring an intervention prior to the point that emergent medical care is needed. Information in the alert emails will include the participant's Medical Reference Number (MRN), initials, date of birth, and details about the symptom(s) that generated the alert. Pod nurses instructed to respond to any clinical alerts (sent via email) as soon as possible following standard of care.
Study: NCT02192021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micro needle array-Doxorubicin (MNA-D)
Description: MNA-D patches will be applied to 3-4 CTCL skin patches or plaques at each weekly visit (4/cycle). The initial safety, dose-finding phase will include one cycle of applications and the second phase will include weekly applications (4/cycle) for up to 6-8 cycles.
Study: NCT02311868

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SYNBIOTIC (Probinul neutro®)
Description: Probinul neutro® assumed three times a day far from meals as 5 g powder packets dissolved in water. Probinul neutro® contains 5×109 Lactobacillus plantarum, 2×109 Lactobacillus casei subp. rhamnosus and 2×109 Lactobacillus gasseri, 1×109 Bifidobacterium infantis and 1×109 Bifidobacterium longum, 1×109 Lactobacillus acidophilus, 1×109 Lactobacillus salivarus and 1×109 Lactobacillus sporogenes and 5×109 Streptococcus termophilus, prebiotic inulin (2.2 g; VB Beneo Synergy 1) and 1.3 g of tapioca-resistant starch.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Tapioca-resistant starch powder similar in colour, texture and taste to the symbiotic mixture, assumed three times a day far from meals as 5 g powder packets dissolved in water.
Study: NCT00482573

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental local anesthesia
Description: * 2% lidocaine solution with epinephrine 1:100,000~* infusion of 1,8 mL (one cartridge)~* Technic: modified anesthesia of the periodontal ligament (PDLm injection) was performed applying The Wand II Computerized System (Milestone International)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dental local anesthesia
Description: * 2% lidocaine solution without vasoconstrictor~* infusion of 1,8 mL (one cartridge)~* Technic: modified anesthesia of the periodontal ligament (PDLm injection) was performed applying The Wand II Computerized System (Milestone International)
Study: NCT03842254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Description: Subcutaneous injection of erythropoietin 10,000 units
Study: NCT03226210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspart insulin or lipro insulin
Description: After completing OGTTS, enrolled subjects (new diagnosed T2DM) were randomly assigned into two groups: NovoRapid group (group Asp, Novo Nordisk, Bagsvaerd, Denmark) and Prandilin group (group Lis, Gan \& Lee pharmaceuticals, Beijing, China) in CSII, combined with metformin (Bristol-Myers Squibb, USA) therapy. During insulin intensive therapy, every patient general use 1.5g metformin per day. If the patient is unable to tolerate the side effects of metformin, such as diarrhea, nausea, vomiting, allergies, etc., the daily dose of metformin is reduced to 1.0g. If the patients are still unable to tolerate the daily 1.0g of metformin, exit from this study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspart insulin or lipro insulin
Description: After completing OGTTS, enrolled subjects (new diagnosed T2DM) were randomly assigned into two groups: NovoRapid group (group Asp, Novo Nordisk, Bagsvaerd, Denmark) and Prandilin group (group Lis, Gan \& Lee pharmaceuticals, Beijing, China) in CSII, combined with metformin (Bristol-Myers Squibb, USA) therapy. During insulin intensive therapy, every patient general use 1.5g metformin per day. If the patient is unable to tolerate the side effects of metformin, such as diarrhea, nausea, vomiting, allergies, etc., the daily dose of metformin is reduced to 1.0g. If the patients are still unable to tolerate the daily 1.0g of metformin, exit from this study.
Study: NCT04059003

Intervention type: DRUG
Intervention: Taxanes or/and anthracycline-based therapy
Description: Taxanes or/and anthracycline-based therapy will be used in this group. That is, intravenous injection of 90 mg/m2 epirubicin (trade name: Pharmorubicin, Pfizer, Shanghai, China; drug approval number: H20100155) + 135 mg/m2 paclitaxel liposome (trade name: Taxotere, Sanofi (Hangzhou) Pharmaceutical Co., Ltd., Hangzhou, China; drug approval number: J20090104), every 3 weeks as a course of treatment. The efficacy will be evaluated every 2 courses. After the 6th course, mastectomy will be performed according to the patient's conditions.

Intervention type: DRUG
Intervention: Taxanes or/and anthracycline-based therapy
Description: Taxanes or/and anthracycline-based therapy will be used in this group. That is, intravenous injection of 90 mg/m2 epirubicin (trade name: Pharmorubicin, Pfizer, Shanghai, China; drug approval number: H20100155) + 135 mg/m2 paclitaxel liposome (trade name: Taxotere, Sanofi (Hangzhou) Pharmaceutical Co., Ltd., Hangzhou, China; drug approval number: J20090104), every 3 weeks as a course of treatment. The efficacy will be evaluated every 2 courses. After the 6th course, mastectomy will be performed according to the patient's conditions.
Study: NCT02686047

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HYAJOINT Plus
Description: The patients in the HYAJOINT Plus group received one intraarticular injection of 3 ml HYAJOINT Plus (2% microbial fermented HA, 20 mg/ml).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Synvisc-One
Description: The Synvisc-One group received one injection of 6 ml Synvisc-One (0.8% avian derived HA, 8 mg/ml).
Study: NCT03868072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELJANZ 5Mg Tablet
Description: XELJANZ 5Mg Tablet 1T single oral administration under fasting

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELJANZ 5Mg Tablet
Description: XELJANZ 5Mg Tablet 1T single oral administration under fasting

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chong Kun Dang Tofacitinib Tablet
Description: Chong Kun Dang Tofacitinib Tablet 1T single oral administration under fasting

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chong Kun Dang Tofacitinib Tablet
Description: Chong Kun Dang Tofacitinib Tablet 1T single oral administration under fasting
Study: NCT03774485

Intervention type: DEVICE
Intervention: G-Tech Gutcheck Myoelectric recording device
Description: Three G-Tech patches are placed on the abdomen of the patient to record myoelectric activity.

Intervention type: DEVICE
Intervention: G-Tech Gutcheck Myoelectric recording device
Description: Three G-Tech patches are placed on the abdomen of the patient to record myoelectric activity.

Intervention type: DEVICE
Intervention: G-Tech Gutcheck Myoelectric recording device
Description: Three G-Tech patches are placed on the abdomen of the patient to record myoelectric activity.
Study: NCT01411839

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT-AD)
Description: CBT-AD is a therapy program intervention that uses one-on-one and face-to-face patient-therapist sessions.
Study: NCT01886378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UX007
Study: NCT01688830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655075

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00005597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: 200 mg/m\^2/day, PO, on Days 1-5 of each 28 day cycle.
Study: NCT03801915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MVT-5873
Description: 1 mg/kg or 3 mg/kg for pre-operative dose, 1 mg/kg during post-operative period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MVT-5873
Description: 1 mg/kg or 3 mg/kg for pre-operative dose, 1 mg/kg during post-operative period

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pancreatectomy or hepatectomy
Description: Pancreatectomy or hepatectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pancreatectomy or hepatectomy
Description: Pancreatectomy or hepatectomy
Study: NCT00446992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: 16-week open trial of olanzapine. The patients were started on a dose of 15 mg/d by mouth, which could be adjusted to as low as 10 mg/d or as high as 40 mg/d, based on clinical response. The trial began while they were hospitalized and continued after discharge.
Study: NCT04210869

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mixed Nuts
Description: Study volunteers will receive daily 60 g of mixed nuts (15 g walnut, 15 g cashew, 15 g hazelnut, 15 g pistachio) for 16 weeks.
Study: NCT03435757

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OFD+IMP+CPS
Description: open flap debridement (OFD) and intramarrow penetration (IMP) plus calcium phosphosilicate putty

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OFD+IMP
Description: open flap debridement (OFD) and intramarrow penetration (IMP)
Study: NCT00685633

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bicalutamide
Description: Given orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bicalutamide
Description: Given orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: enzastaurin hydrochloride
Description: Given orally
Study: NCT04061395

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: See study arm description.
Study: NCT01211288

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Astra implants
Description: Root form OsseoSpeed TX Astra Tech Implant System

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Astra implants
Description: Root form OsseoSpeed TX Astra Tech Implant System
Study: NCT00731120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Encapsulated vortioxetine immediate-release tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Encapsulated vortioxetine immediate-release tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vortioxetine placebo-matching capsules
Study: NCT04169230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram
Description: Single dose administration of citalopram (20mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Single dose administration lactose placebo tablet
Study: NCT05566496

Intervention type: DIAGNOSTIC_TEST
Intervention: Brain MRI
Description: All participants receive brain MRI evaluation and clinical evaluation of tic severity.

Intervention type: DIAGNOSTIC_TEST
Intervention: Brain MRI
Description: All participants receive brain MRI evaluation and clinical evaluation of tic severity.
Study: NCT03802942

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucerna
Description: 1 bottle in the morning with breakfast and 1 bottle in the evening with dinner
Study: NCT00520169

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intranasal ketamine
Description: A randomized, open label, single center, single-dose study to determine the absolute bioavailability and nasopharyngeal absorption of PMI-150 (intranasal ketamine) 30mg in healthy adult volunteers. The Pilot Phase will be conducted as a parallel study, while the Test Phase will be conducted as a crossover study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal ketamine
Description: A randomized, open label, single center, single-dose study to determine the absolute bioavailability and nasopharyngeal absorption of PMI-150 (intranasal ketamine) 30mg in healthy adult volunteers. The Pilot Phase will be conducted as a parallel study, while the Test Phase will be conducted as a crossover study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intranasal ketamine
Description: A randomized, open label, single center, single-dose study to determine the absolute bioavailability and nasopharyngeal absorption of PMI-150 (intranasal ketamine) 30mg in healthy adult volunteers. The Pilot Phase will be conducted as a parallel study, while the Test Phase will be conducted as a crossover study.
Study: NCT01513980

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: self-monitoring for patients with severe COPD
Description: Patients are equipped with a telemonitoring kit composed by a portable wrist-clinic device for clinical parameters measuring and a gateway device for data transmission.~The patient can monitor pulse-oxymetry and heart rate with a frequency set by the clinician in the personalised treatment plan. Data are transmitted to a regional eHealth centre where a group of operators keeps these information under control and alert the reference clinician in case of worsening of symptoms. CAT questionnaire is monthly administrated by phone to the patients

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nurse-monitoring for patients with severe COPD
Description: A nurse is in charge of data collection during home visits with a frequency set by the lung specialist depending to the patient clinical conditions. The nurse uses portable biomedical devices to measure pulse-oxymetry, heart rate, spirometry and if scheduled an arterial blood gas test. Data are transmitted to the clinician who checks them on his laptop in the hospital and completes the visit with the medical report.
Study: NCT02791945

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medical Management Counseling
Description: Brief alcohol counseling

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Medical Management Counseling
Description: Brief alcohol counseling

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: Experimental supplement

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study: NCT03933527

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: making staining beverage rinse during in-office tooth bleaching
Description: the subjects in experimental group should make staining beverage(coffee or tea) rinse for 30 second, four times daily.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: making staining beverage rinse during in-office tooth bleaching
Description: the subjects in experimental group should make staining beverage(coffee or tea) rinse for 30 second, four times daily.
Study: NCT00795613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESCALATED BEACOPP
Description: Esc.BEACOPP Bleomicine10 mg/m2/ev/die 8° VP-16 200 mg/m2/ev/die1°- 3° Doxorubicine35 mg/m2/ev/die 1° Cyclophosphamide1250 mg/m2/ev/die 1° Vincristine1,4 mg/m2(max dose 2 mg)/ev/die 8° Procarbazine100 mg/m2/b.m./die 1°- 7° Prednison40 mg/m2/b.m./die 1°-14° G-CSF300mcg/die s/c from day 8 until PMN\>1000/ul Recycle every 21 days Esc.R-BEACOPP as above plus Rituximab 375 mg/m2/ev/ die 1° Recycle every 21 days Baseline BEACOPP Bleomicine10 mg/m2/ev/die 8° VP-16 100 mg/m2/ev/die 1°-3° Doxorubicine25 mg/m2/ev/die 1° Cyclophosphamide650 mg/m2/ev/die 1° Vincrinstine1,4 mg/m2(max dose 2 mg)/ev/die 8° Procarbazine100 mg/m2/os/die 1°-7° Prednison40 mg/m2/os/die 1°-14° Recycle every 21 days Baseline R-BEACOPP as above plus Rituximab375 mg/m2/ev/ die 1° Recycle every 21 days
Study: NCT02086578

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breast MRI

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breast MRI

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breast-Q© questionnaire

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breast-Q© questionnaire

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Multi-Beam IMRT
Description: The radiation dose (50-50.4 Gy/25-28 fractions in approximately 5-6 weeks), treatment-planning and delivery aspects are according to departmental guidelines for breast IMRT.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Multi-Beam IMRT
Description: The radiation dose (50-50.4 Gy/25-28 fractions in approximately 5-6 weeks), treatment-planning and delivery aspects are according to departmental guidelines for breast IMRT.
Study: NCT03278249

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Atkins Ketogenic Diet
Description: Less than 20 grams of carbohydrates per day